JIN-A02 is under clinical development by J Ints Bio and currently in Phase II for Non-Small Cell Lung Cancer. According to GlobalData, Phase II drugs for Non-Small Cell Lung Cancer have a 39% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how JIN-A02’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
JIN-A02 is under development for the treatment of epithelial growth factor receptor (EGFR) T790M or C797S mutation positive advanced non-small cell lung cancer (NSCLS). It is administered through oral route. It acts by targeting epidermal growth factor receptor-tyrosine kinase.
J Ints Bio overview
J Ints Bio is a bioscience company specializing in the development of anticancer drugs and orphan drugs. J Ints Bio is headquartered in Seoul, South Korea.
For a complete picture of JIN-A02’s drug-specific PTSR and LoA scores, buy the report here.